Cancer risk with alemtuzumab following kidney transplantation

Clinical Transplantation

Volumn 27, Issue 3, 2013, Pages

  Puttarajappa, C ^a   Yabes, J ^a   Bei, L ^a   Shah, N ^a   Bernardo, J ^a   Mccauley, J ^a   Basu, A ^b   Tan, H ^b   Shapiro, R ^b   Unruh, M ^a   Wu, C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab; Cancer; Immunosuppression; Kidney transplant

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CALCINEURIN INHIBITOR; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; RAPAMYCIN; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CHEMICALLY INDUCED; COMPLICATION; KIDNEY DISEASES; MIDDLE AGED; MORTALITY; NEOPLASMS; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84878652631     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12094     Document Type: Article

References (45)

1. 2010 OPTN/SRTR annual report. http://www.srtr.org/annual_reports/2010/506a_ki.htm.
2. Calne R, Moffatt SD, Friend PJ et al. Alemtuzumab 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999: 68: 613.
3. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Alemtuzumab). Transplantation 2003: 76: 120.
4. Knechtle SJ, Pirsch JD, Fechner J Jr et al. Alemtuzumab induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003: 3: 722.
5. Watson CJE, Bradley JA, Friend PJ et al. Alemtuzumab (Alemtuzumab 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005: 5: 1347.
6. Kirk AD, Mannon RB, Kleiner DE et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxypergualin. Transplantation 2005: 80: 1051.
7. Barth RN, Janus CA, Lillesand CA et al. Outcomes at 3 years of prospective pilot study of Alemtuzumab and sirolimus immunosuppression for renal transplantation. Transplant Int 2006: 19: 885.
8. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005: 5: 3009.
9. Knechtle SJ, Fernandez LA, Pirsch JD et al. Alemtuzumab in renal transplantation: the University of Wisconsin experience. Surgery 2004: 136: 754.
10. Shapiro R, Basu A, Tzan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Alemtuzumab. J Am Coll Surg 2005: 200: 505.
11. Tan HP, Kaczorowski DJ, Basu M et al. Living donor renal transplantation using Alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006: 6: 2409.
12. Ciancio G, Sageshima J, Gaynor JJ et al. The use of Alemtuzumab as induction therapy to achieve steroid avoidance in African-American and Hispanic first renal transplant recipients [abstract]. Am J Transplant 2006: 1324: 513.
13. Vathsala A, Ona ET, Tan SY et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005: 80: 765.
14. Ortiz J, Palma-Vargas J, Wright F et al. Campath induction for kidney transplantation: report of 297 cases. Transplantation 2008: 85: 1550.
15. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA. Stuart FP Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction - long term results. Am J Transplant 2005: 5: 2539.
16. Hanaway MJ, Woodle ES, Mulgaonkar S et al. Alemtuzuamab induction in renal transplantation. N Engl J Med 2011: 364: 1909.
17. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008: 22: 200.
18. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a randomized trial. Am J Transplant 2008: 8: 1480.
19. Farney AC, Doares W, Rogers J et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009: 88: 810.
20. Wu C, Evans I, Joseph R et al. Comorbid conditions in kidney transplantation: association with graft and patient survival. J Am Soc Nephrol 2005: 16: 3437.
21. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988: 16: 1141.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk." J Am Stat Assoc 1999: 94: 496.
23. Scheike TH, Zhang MJ, Gerds TA. Predicting cumulative incidence probability by direct binomial regression. Biometrika 2008: 95: 205.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2011. ISBN 3-900051-07-0, URL http://www.R-project.org.
25. Gray RJ. cmprsk: Subdistribution Analysis of Competing Risks. R Package Version 2.2-2. 2011. http://CRAN.R-project.org/package=cmprsk.
26. Scheike TH, Zhang MJ. Analyzing Competing Risk Data Using the R timereg Package. J Stat Softw 2011: 38: 1. URL http://www.jstatsoft.org/v38/i02/.
27. Engels EA, Pfeiffer RM, Fraumeni JF Jr et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011: 306: 1891.
28. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009: 125: 1747.
29. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995: 60: 183.
30. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010: 10: 1889.
31. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007: 7: 941. pmid:17331115.
32. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006: 296: 2823.
33. Adami J, Gäbel H, Lindelöf B et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003: 89: 1221.
34. Kyllönen, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl Int 2000: 13(Suppl 1): S394.
35. Serraino D, Piselli P, Angeletti C et al. Risk of Kaposi's sarcoma and of other cancers in Italian renal transplant patients. Br J Cancer 2005: 92: 572.
36. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004: 4: 905.
37. Wimmer CD, Rentsch M, Crispin A et al. The Janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 2007: 71: 1271.
38. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immmunosurveillance to tumor escape. Nat Immunol 2002: 3: 991.
39. Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant 2008: 8: 2205.
40. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003: 76: 1289.
41. Bustami RT, Ojo AO, Wolfe RA et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004: 4: 87.
42. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006: 81: 1227.
43. Kirk AD, Cherikh WS, Ring M et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007: 7: 2619.
44. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998: 351: 623.
45. Surveillance Epidemiology and End Results (SEER) data. http://seer.cancer.gov/csr/1975_2008/browse_csr.php?section=35&page=sect_35_table.01.html.